Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Weijiao Du
Observed names:
Wei-Jiao Du,
Wei‐jiao Du
Institution:
Tianjin Medical University Cancer Institute and Hospital
Observed institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
ORCID:
0000-0003-2267-2644
Observed ORCID:
0000-0003-2267-2644
OpenAlex ID:
A5060844380
Myeloid-Derived Suppressor Cells Suppress Antitumor Immune Responses through IDO Expression and Correlate with Lymph Node Metastasis in Patients with Breast Cancer
2013
·
Jinpu Yu
, Weijiao Du
, et al.
·
The Journal of Immunology
·
658
Primary hepatic angiosarcoma and potential treatment options
2013
·
Ya‐wen Zheng
, Xin‐wei Zhang
, et al.
·
Journal of Gastroenterology and Hepatology
·
120
PDF
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial
2024
·
Qiu-Zhong Pan
, Jing-Jing Zhao
, et al.
·
Signal Transduction and Targeted Therapy
·
42
PDF
A Phase IB Trial of Autologous Cytokine‐Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death‐1, plus Chemotherapy in Patients with Advanced Non‐Small‐Cell Lung Cancer
2022
·
Li Zhou
, Yanjuan Xiong
, et al.
·
Clinical Lung Cancer
·
36
PDF
Autologous cytokine‐induced killer ( CIK ) cells enhance the clinical response to PD‐1 blocking antibodies in patients with advanced non‐small cell lung cancer: A preliminary study
2020
·
Ying Han
, Di Mu
, et al.
·
Thoracic Cancer
·
27
PDF
Ferritin as a diagnostic, differential diagnostic, and prognostic marker for immune-related adverse events
2021
·
Weihong Zhang
, Yuan Meng
, et al.
·
Cancer Biology and Medicine
·
14
Response to gefitinib/crizotinib combination in a pulmonary sarcomatoid carcinoma patient harboring concurrent EGFR mutation and MET amplification
2021
·
Xiaomeng Wang
, Jie Cao
, et al.
·
Clinical Case Reports
·
10
PDF
The spatial landscape of T cells in the microenvironment of stage III lung adenocarcinoma
2024
·
Ziqing Zeng
, Weijiao Du
, et al.
·
The Journal of Pathology
·
9
Association of concomitant H1 antihistamine and immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer: a cohort study
2024
·
Wei-Hong Zhang
, Bing-Xue Li
, et al.
·
Translational Lung Cancer Research
·
7
Pathologic complete response to immune checkpoint inhibitor in a stage IIIB ovarian clear cell carcinoma patient with POLE mutation resistant to platinum-based chemotherapy: a case report
2022
·
Shuzhan Li
, Jiali Zhang
, et al.
·
Gland Surgery
·
2
PDF
Vemurafenib for BRAF V600‐mutant Erdheim–Chester disease presenting with bilateral orbital involvement
2023
·
Xiaomeng Wang
, Jie Cao
, et al.
·
Clinical Case Reports
·
1
PDF
Autologous Cytokine-Induced Killer (CIK) Cell Immunotherapy plus Sintilimab and Chemotherapy in Advanced Non‒Small-Cell Lung Cancer: 3-Year Outcomes From the Phase Ib CCICC-002a Study
2025
·
Weihong Zhang
, Yanping Chen
, et al.
·
Research Square
Examining the spatial distribution of tumor-infiltrating immune cells in patients with stage I to IIIA LUAD
2024
·
Weijiao Du
, Fan Yang
, et al.
·
Journal of Leukocyte Biology
An Analysis of Clinical and Pathological Characteristics of 14431 Cases of Thyroid Carcinoma
2022
·
Xiaomeng Wang
, Na Pan
, et al.
·
International Journal of Surgery Oncology
PDF
Clinical efficacy of cytokine-induced killer cells for 87 patients with non-small cell lung cancer
2012
·
Chunjuan Du
, Liang Liu
, et al.
·
Clinical Oncology and Cancer Research
Expression of IDO in tumor induced myeloid-derived suppressor cells and its mechanism
2011
·
Weijiao Du
, Jinpu Yu
, et al.
·
Clinical Oncology and Cancer Research
Myeloid derived suppressor cells enhance tumour immune escape
2011
·
Weijiao Du
, Shui Cao
, et al.
·
Int J Immunol
Show more works
View as search
Works count:
17
Citation count:
926
H-index:
8
I10-index:
7
Year
Topic
Type